Who is sponsoring NCT03691324?

NCT03691324 is sponsored by Oslo University College.

What drugs are being tested in NCT03691324?

Interventions in NCT03691324: Inhalation technique training and discharge service.

What condition does NCT03691324 study?

NCT03691324 studies Pulmonary Disease, Chronic Obstructive.

Is NCT03691324 still recruiting?

NCT03691324 is currently completed. Last updated 25 February 2021.

Last reviewed 2021-02-25 · How we verify

NCT03691324

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study

Completed NA Last updated 25 February 2021

What this trial tests

NA trial testing Inhalation technique training and discharge service in Pulmonary Disease, Chronic Obstructive in 40 participants. Completed in 15 January 2021.

Timeline

26 September 2018

Primary endpoint
15 November 2020

15 January 2021

Quick facts

Lead sponsor	Oslo University College
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	40
Start date	26 September 2018
Primary completion	15 November 2020
Estimated completion	15 January 2021
Sites	1 location across Norway

Drugs / interventions tested

Inhalation technique training and discharge service

Conditions studied

Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →

Sponsor

Oslo University College

Who can join

18 and older, any sex, with Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inhalation drugs are essential in the treatment of COPD, in controlling symptoms and preventing exacerbations. The aim of this pilot study is to collect data necessary for the planning of future efficacy trials. We plan to assess the value of providing training in inhalation technique to hospitalized COPD patients. Data on rehospitalizations will be collected from the hospital's medical records and from the National Patient Registry . The inhalation technique of all recruited patients will de assessed at baseline. The patients will then be randomised 1:1 to the intervention or standard care group. The intervention consists of a drug counselling, focusing on inhalation technique. In addition patients in the intervention group will have their medicines personally delivered from the hospital pharmacy at discharge (discharge service). Patients will be asked to fill in questionnaires evaluating the inhalation training and the discharge service

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of pharmacist-led inhaler technique assessment service on readmissions in hospitalized COPD patients: a randomized, controlled pilot study.
Kebede AT, Trapnes E, Lea M, Abrahamsen B, et al · · 2022 · cited 7× · PMID 35624509 · DOI 10.1186/s12890-022-02004-z
The Impact of Pharmacist-Led Interventions on the Treatment of Chronic Obstructive Pulmonary Disease Patients.
Hahn K, Flamm M, Flamm M, Wernly B. · · 2025 · PMID 40659017 · DOI 10.1159/000547390

Verify or expand the search:

Other recruiting trials for Pulmonary Disease, Chronic Obstructive

Currently open trials in the same condition.

NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03691324 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oslo University College
Last refreshed: 25 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03691324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing